Your browser doesn't support javascript.
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
Saito, Akatsuki; Tamura, Tomokazu; Zahradnik, Jiri; Deguchi, Sayaka; Tabata, Koshiro; Anraku, Yuki; Kimura, Izumi; Ito, Jumpei; Yamasoba, Daichi; Nasser, Hesham; Toyoda, Mako; Nagata, Kayoko; Uriu, Keiya; Kosugi, Yusuke; Fujita, Shigeru; Shofa, Maya; Monira Begum, Mst; Shimizu, Ryo; Oda, Yoshitaka; Suzuki, Rigel; Ito, Hayato; Nao, Naganori; Wang, Lei; Tsuda, Masumi; Yoshimatsu, Kumiko; Kuramochi, Jin; Kita, Shunsuke; Sasaki-Tabata, Kaori; Fukuhara, Hideo; Maenaka, Katsumi; Yamamoto, Yuki; Nagamoto, Tetsuharu; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Ueno, Takamasa; Schreiber, Gideon; Takaori-Kondo, Akifumi; Shirakawa, Kotaro; Sawa, Hirofumi; Irie, Takashi; Hashiguchi, Takao; Takayama, Kazuo; Matsuno, Keita; Tanaka, Shinya; Ikeda, Terumasa; Fukuhara, Takasuke; Sato, Kei.
  • Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan.
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Zahradnik J; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel; First Medical Faculty at Biocev, Charles University, Vestec, Prague, Czechia.
  • Deguchi S; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Tabata K; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Anraku Y; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Kimura I; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yamasoba D; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Medicine, Kobe University, Kobe, Japan.
  • Nasser H; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Toyoda M; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Nagata K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Fujita S; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Shofa M; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
  • Monira Begum M; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Shimizu R; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Oda Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Suzuki R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Ito H; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Nao N; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Wang L; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Tsuda M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Yoshimatsu K; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Kuramochi J; Interpark Kuramochi Clinic, Utsunomiya, Japan; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
  • Kita S; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Sasaki-Tabata K; Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Fukuhara H; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Maenaka K; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan; Division of Pathogen Structure, International I
  • Yamamoto Y; HiLung Inc., Kyoto, Japan.
  • Nagamoto T; HiLung Inc., Kyoto, Japan.
  • Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Ueno T; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Schreiber G; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Sawa H; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sap
  • Irie T; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Takayama K; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
  • Matsuno K; One Health Research Center, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo,
  • Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp.
  • Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp.
  • Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. Electronic address: fukut@pop.med.hokudai.ac.jp.
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Scienc
Cell Host Microbe ; 30(11): 1540-1555.e15, 2022 11 09.
Article in English | MEDLINE | ID: covidwho-2130372
ABSTRACT
The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.10.003

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.10.003